|
Jun 06, 2023
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Jun 01, 2023
|
BioCryst to Present at Upcoming Investor Conference
|
|
|
May 31, 2023
|
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress
|
|
|
May 22, 2023
|
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chile
|
|
|
May 04, 2023
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
May 03, 2023
|
BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update
|
|
|
Apr 27, 2023
|
BioCryst Presents New Long-term Data Demonstrating Consistently High Attack-free Status Among Hereditary Angioedema Patients with ORLADEYO® (berotralstat)
|
|
|
Apr 19, 2023
|
BioCryst to Report First Quarter 2023 Financial Results on May 3
|
|
|
Apr 18, 2023
|
BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon
|
|
|
Apr 12, 2023
|
BioCryst to Present at Upcoming Investor Conferences
|
|
